Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00710710
Recruitment Status : Completed
First Posted : July 4, 2008
Last Update Posted : May 16, 2014
Information provided by:
Boehringer Ingelheim

Brief Summary:
The trial is conducted in order to evaluate the efficacy, safety and pharmacokinetics of BI 2536 in the treatment of unresectable advanced pancreatic cancer as first line or second line therapy. A secondary aim is to identify the most suitable dosage regimen for the further phase II and III clinical programme of BI 2536. To achieve this objective, two dosage regimens are compared in patients receiving first line therapy.

Condition or disease Intervention/treatment Phase
Pancreatic Neoplasms Drug: BI 2536 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 89 participants
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: An Open, Randomised, Clinical Phase II Trial in Patients With Unresectable Advanced Pancreatic Cancer Investigating the Efficacy, Safety, and Pharmacokinetics of BI 2536 Administered in Repeated 3-week Cycles as a Single i.v. Dose of 200 mg on Day 1 or as 60 mg Doses on Days 1, 2, and 3
Study Start Date : August 2006
Actual Primary Completion Date : October 2008

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Objective Response (RECIST) [ Time Frame: 3 weeks ]
  2. PFS [ Time Frame: every 6 weeks ]

Secondary Outcome Measures :
  1. Tumour control ("objective response" or "stable disease" after the fourth treatment course) [ Time Frame: 12 weeks ]
  2. duration of overall response [ Time Frame: every 6 weeks ]
  3. overall survival [ Time Frame: every 6 weeks ]
  4. best response (confirmed and unconfirmed) evaluated according to the RECIST criteria every other course [ Time Frame: 3 weeks ]
  5. One-year survival [ Time Frame: 3 weeks ]
  6. Carbohydrate antigen (CA)19-9 response [ Time Frame: 3 weeks ]
  7. Quality of life assessment, including clinical benefit response [ Time Frame: 3 weeks ]
  8. Incidence and intensity of AEs graded according to CTCAE [ Time Frame: approximately twice a week ]
  9. Dose limiting toxicity (DLT) [ Time Frame: 3 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. male or female patient aged 18 years or older
  2. patient with confirmed diagnosis of unresectable, either locally advanced or metastatic, ductal adenocarcinoma of the pancreas
  3. patient who is either chemonaïve (for the first line cohorts), or who presents with progressive disease under first line chemotherapy with a gemcitabine based regimen (for the second line cohort)
  4. Karnofsky performance status of ¿ 70% for the first line cohorts, and Karnofsky performance status ¿ 50% for the second line cohort
  5. patient with at least one measurable tumour lesion that can accurately be measured by magnetic resonance imaging (MRI), or computed tomography (CT) in at least one dimension (longest diameter to be recorded)
  6. life expectancy of at least three months
  7. patient must have given written informed consent consistent with the guidelines of the international conference on harmonisation for good clinical practice (ICH-GCP) as well as with local legislation

Exclusion Criteria:

  1. prior adjuvant chemotherapy (for first line cohorts only)
  2. ampullary carcinoma of the pancreas
  3. hypersensitivity to the trial drug or the excipients
  4. persistence of toxicities of prior anti cancer therapies which are deemed to be clinically relevant
  5. known second malignancy requiring therapy
  6. brain metastases which are symptomatic or require therapy
  7. absolute neutrophil count less than 1.500/mm3
  8. platelet count less than 100.000/mm3
  9. haemoglobin less than 9 mg/dl
  10. aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 2.5 times the upper limit of normal, or AST or ALT greater than 5 times the upper limit of normal in case of known liver metastases
  11. bilirubin greater than 3.0 mg/dl (> 52 ¿mol/l, SI unit equivalent) under adequate drainaging measures (in case of obstructive jaundice)
  12. serum creatinine greater than 2.0 mg/dl
  13. concomitant intercurrent illnesses including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social situation that would limit compliance with trial requirement or which are considered relevant for the evaluation of the efficacy or safety of the trial drug
  14. radiotherapy within the past four weeks prior to treatment with the trial drug
  15. hormone- or immunotherapy or therapy with a biologic response modifier within the past four weeks
  16. treatment with any other investigational drug within the past four weeks
  17. men or women who are sexually active and unwilling to use a medically acceptable method of contraception (e.g. abstinence, condom with spermicidal coating, diaphragm with spermicidal coating, oral contraceptive, progesterone implant, sterilisation) during the trial
  18. pregnancy or lactation
  19. patients unable to comply with the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00710710

1216.10.43001 Boehringer Ingelheim Investigational Site
Wien, Austria
1216.10.49013 Boehringer Ingelheim Investigational Site
Celle, Germany
1216.10.49009 Boehringer Ingelheim Investigational Site
Düsseldorf, Germany
1216.10.49007 Boehringer Ingelheim Investigational Site
Essen, Germany
1216.10.49001 Boehringer Ingelheim Investigational Site
Freiburg/Breisgau, Germany
1216.10.49005 Boehringer Ingelheim Investigational Site
Hamburg, Germany
1216.10.49010 Boehringer Ingelheim Investigational Site
Herne, Germany
1216.10.49008 Boehringer Ingelheim Investigational Site
München, Germany
1216.10.49003 Boehringer Ingelheim Investigational Site
Stuttgart, Germany
1216.10.49002 Boehringer Ingelheim Investigational Site
Ulm, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim Identifier: NCT00710710     History of Changes
Other Study ID Numbers: 1216.10
First Posted: July 4, 2008    Key Record Dates
Last Update Posted: May 16, 2014
Last Verified: April 2014

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases